About US
Contact us
-
Acute Ischemic Stroke: Global Market Value to Grow Significantly by 2017, but Clinical Trial Challenges RemainThe acute ischemic stroke (AIS) therapeutics market in the six major countries — the US, France, Germany, Italy, Spain and UK — is forecast to jump from $531 million in 2012 to $1.2 billion by 2017, a2013/12/23
-
Molecular Profiles Joins Leading Consortium to Drive Paediatric Formulation DevelopmentA collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant. The UK-wi2013/12/23
-
Merck and CNIO sign licence agreement for development of new cancer drugsMerck's biopharmaceutical division Merck Serono and the Spanish National Cancer Research Centre (CNIO) have signed an agreement in Madrid to collaborate in the developing of cancer drugs. This global2013/12/20
-
FDA Endorses, Pushes for Abuse-Resistant Opioid Formulations: Transition to Disrupt Pain MarketThe opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration’s (FDA’s) promotion of TRF therapies could well result in the departure of non-TRF ther2013/12/20
-
Navidea seeks FDA approval for Lymphoseek injection to detect SLN in cancer patientsNavidea Biopharmaceuticals has filed a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for its Lymphoseek injection, designed for the detection2013/12/19
-
Pfizer gives Teva a lift with deal for Viagra generic launch in 2017After years of wrangling over Pfizer's ($PFE) patent onViagra, Teva Pharmaceutical Industries ($TEVA) has made a deal. Under an agreement with Pfizer, the Israeli generics giant can launch its version2013/12/19
-
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in EuropeBiogen Idec and Samsung Bioepishave announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialise anti-TNF biosimilar product candidates i2013/12/18
-
NovaBiotics Initiates Development of Orphan Drug in Cystic FibrosisNovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company has initiated the development of an inhaled form of Lynovex, its treatment for cystic fibrosis (CF). Lynovex is an orphan dr2013/12/18
-
Recipharm Subsidiary Files Infectious Disease Drug Applicatio​n in European MarketRPH Pharmaceuticals AB, a subsidiary ofRecipharm AB,has filed anapplication for an infectious disease drug product in a range of European countries. The product has been developed through a partnershi2013/12/17
-
Recipharm Subsidiary Files Infectious Disease Drug Applicatio​n in European MarketRPH Pharmaceuticals AB, a subsidiary ofRecipharm AB,has filed anapplication for an infectious disease drug product in a range of European countries. The product has been developed through a partnershi2013/12/17